Core Viewpoint - The company is adapting to a changing market environment and competitive landscape by focusing on technology-driven strategies and increasing investment in research and innovation to enhance profitability [1] Group 1: Strategic Focus - The company will concentrate on the development of new veterinary drugs to provide high-quality and cost-effective animal health products and solutions for the aquaculture industry, thereby improving the efficiency of its clients' farming operations [1] - The company aims to deepen its "raw material-formulation integration" strategy to ensure stable raw material supply and controllable costs, which will enhance competitive barriers and increase product market competitiveness [1] Group 2: Business Expansion - The company is accelerating its layout in the pet medicine sector by leveraging its advantages in research and innovation to enrich its product matrix and complete the pet business segment, creating a new growth driver [1] - The company is implementing an "outbound" strategy to actively explore overseas markets, which will help mitigate the cyclical impacts on domestic business [1]

Core Viewpoint - Reap Bio announced on November 4 that the total number of shareholders is expected to be approximately 25,000 by October 31, 2025 [2] Summary by Categories - **Company Information** - Reap Bio's total number of shareholders is projected to reach around 25,000 by October 31, 2025 [2]

Core Insights - The animal health sector experienced a decline of 0.35% on November 3, with Reap Bio leading the losses [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - Hai Li Biological (603718) closed at 7.02, up 2.03% with a trading volume of 101,600 shares and a turnover of 70.93 million yuan [1] - Shen Lian Biological (688098) closed at 11.36, up 1.43% with a trading volume of 133,100 shares and a turnover of 150 million yuan [1] - Yong Shun Biological (920729) closed at 10.09, up 1.00% with a trading volume of 23,800 shares and a turnover of 24.09 million yuan [1] - The worst performer was Reap Bio (300119), which closed at 21.01, down 2.51% with a trading volume of 103,300 shares and a turnover of 219 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 35.26 million yuan from institutional investors, while retail investors had a net inflow of 26.79 million yuan [2] - The main capital inflow was observed in Shen Lian Biological, with a net inflow of 4.03 million yuan from institutional investors [3] - Conversely, Reap Bio experienced a net outflow of 1.29 million yuan from institutional investors [3]

Investment Rating - The industry rating is "Recommended" [3] Core Insights - The pork price center has significantly risen, leading to a notable reduction in industry losses. The average price of live pigs has increased to 12.51 CNY/kg, a week-on-week rise of 7.20% [2][13] - The agricultural sector is expected to maintain a good development momentum, with grain production projected to be high this year, including summer grain production of 299.48 billion jin and early rice production increasing by 6.8 billion jin, a growth of 1.2% [1][12] - The industry is currently in a supply-demand tug-of-war, with large-scale pig farms adopting strategies to control supply and raise prices, while demand is expected to improve with the arrival of warmer weather and the pickling season [2][13] Summary by Sections Planting Industry Chain - The agricultural sector is implementing key policies to support rural economic development, with a focus on achieving food security and enhancing crop yields through biotechnology [1][12] - Major beneficiaries in the planting sector include Beidahuang and Suqian Agricultural Development, while in the seed industry, companies like Dabeinong and Longping High-Tech are highlighted for their competitive advantages [1][12] Pig Farming - The pig farming industry is still experiencing losses, but there has been a significant reduction in losses compared to the previous week, with self-breeding farms reporting an average loss of 89.33 CNY per head, down nearly 100 CNY [2][13] - The industry is expected to undergo a process of capacity reduction, with a focus on improving quality and efficiency, leading to the gradual elimination of outdated production capacity [2][13] - Recommended stocks in the pig farming sector include companies like DeKang Agriculture, Jingji Zhino, and Muyuan Foods [2][13] Key Agricultural Product Data Tracking - Corn: The average price is 2241.67 CNY/ton, with a week-on-week decrease of 0.66% [27][28] - Wheat: The average price is 2482.11 CNY/ton, with a week-on-week increase of 0.87% [30][32] - Soybeans: The average price is 3996.84 CNY/ton, with a week-on-week increase of 0.06% [41][44] - Cotton: The average price in Xinjiang is 14660 CNY/ton, with a week-on-week increase of 0.15% [46][50] Feed and Vitamin Prices - The average price of pig feed is 2.6 CNY/kg, with a week-on-week decrease of 0.38% [53][55] - The average price of Vitamin E is 50.30 CNY/kg, with a week-on-week increase of 14.58% [62][63]

Investment Rating - The investment rating for the agriculture, forestry, animal husbandry, and fishery industry is "Positive" (maintained) [1] Core Insights - The industry is experiencing a downward trend in pig prices, leading to a de-stocking cycle in pig farming. The profitability of the agriculture sector has turned negative due to a significant drop in pig prices, with Q3 2025 profits down by 58.8% year-on-year [5][14] - The overall revenue for the agriculture sector in Q1-Q3 2025 reached 872.718 billion yuan, a year-on-year increase of 6.44%, while the net profit attributable to shareholders was 35.477 billion yuan, up 10.63% year-on-year [5][14] - The average price of pigs in Q3 2025 was 13.81 yuan/kg, down 28.89% year-on-year, with the lowest price of 10.84 yuan/kg recorded on October 13, 2025 [5][14] Summary by Sections Q3 2025 Observations - The agriculture sector's profit has decreased significantly due to unexpected declines in pig prices, leading to a negative profit margin for the sector [5][14] - The sales gross margin for the industry in Q1-Q3 2025 was 11.79%, a slight increase of 0.12 percentage points year-on-year, while the net profit margin was 4.21%, up 0.21 percentage points year-on-year [6][17] Profitability and Cost Management - The industry is focusing on cost reduction and efficiency improvement, with the expense ratio for Q1-Q3 2025 at 6.64%, down 0.58 percentage points year-on-year [6][17] - In Q3 2025, the sales gross margin fell to 10.71%, a decrease of 4.68 percentage points year-on-year, and the net profit margin dropped to 3.13%, down 4.71 percentage points year-on-year [6][17] Market Performance - The agriculture index outperformed the market by 1.88 percentage points during the week of October 27-31, 2025, with the agriculture index rising by 1.99% [26][28] - Key stocks such as Zhongxing Junye, Weilan Biotechnology, and Luoniushan led the gains in the agriculture sector, with increases of 19.60%, 13.23%, and 9.08% respectively [26][31] Price Tracking - As of October 31, 2025, the average price of pigs was 12.49 yuan/kg, an increase of 0.67 yuan/kg from the previous week, while the average price of piglets was 18.13 yuan/kg, up 0.47 yuan/kg [37][38] - The average price of beef was 66.30 yuan/kg, reflecting a slight increase of 0.09 yuan/kg from the previous week [38]

Core Insights - Zoetis (ZTS) stock is noteworthy due to its high margins, indicating strong pricing power and cash generation capabilities, currently available at a discounted price [2][3] Financial Performance - Revenue growth for Zoetis was 5.3% over the last twelve months and averaged 5.5% over the past three years, indicating stable but not rapid growth [8] - The company reported an operating cash flow margin of approximately 31.2% and an operating margin of 37.5% for the last twelve months [8] - Long-term profitability metrics show an operating cash flow margin of about 28.7% and an average operating margin of 36.6% over the past three years [8] - ZTS stock is currently trading at a price-to-sales multiple of 6.8, reflecting a 24% discount compared to one year ago [8] Market Position - Zoetis provides a range of medicines, vaccines, and diagnostic products for animal health, targeting various livestock species to prevent diseases affecting respiratory, gastrointestinal, and reproductive systems [4]

Core Viewpoint - The animal health sector experienced a rise of 1.53% on October 31, with Shunlian Biological leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 0.81% and 1.14% respectively [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3954.79, down 0.81% [1] - The Shenzhen Component Index closed at 13378.21, down 1.14% [1] - The animal health sector stocks showed varied performance, with Shunlian Biological rising by 9.38% to a closing price of 11.20 [1] Group 2: Stock Performance - Shunlian Biological (688098) led the sector with a closing price of 11.20 and a trading volume of 193,300 shares, amounting to a transaction value of 211 million [1] - Other notable stocks included *ST Lvkang (002868) with a 1.61% increase, closing at 28.44, and Dayu Biological (920970) with a 1.38% increase, closing at 9.53 [1] - The overall trading volume for the animal health sector was significant, with Shunlian Biological contributing 211 million and other stocks like Biological Shares (600201) contributing 283 million [1] Group 3: Fund Flow Analysis - The animal health sector saw a net outflow of 19.81 million from institutional investors and 14.34 million from retail investors, while individual investors contributed a net inflow of 34.15 million [1] - Specific stock fund flows indicated that Biological Shares (600201) had a net inflow of 10.32 million from institutional investors, while Shunlian Biological experienced a net outflow of 12.41 million from retail investors [2] - The overall sentiment in the sector showed mixed results, with some stocks like Biological Shares attracting institutional interest despite overall net outflows [2]

Investment Rating - The report maintains an "Overweight" rating for the agriculture, forestry, animal husbandry, and fishery industry [5][44]. Core Insights - The SW agriculture, forestry, animal husbandry, and fishery industry slightly underperformed the CSI 300 index, declining by 1.1% from October 17 to October 30, 2025, lagging behind the index by approximately 3.08 percentage points [11]. - Among the sub-sectors, only planting and agricultural product processing recorded positive returns, increasing by 1.47% and 0.44% respectively, while fisheries, animal health, breeding, and feed sectors experienced negative returns, declining by 1.22%, 1.63%, 2.56%, and 4.24% respectively [14]. - The overall price of live pigs has rebounded, with the average price rising from 11.17 CNY/kg to 12.56 CNY/kg during the reporting period [23]. - The number of breeding sows as of the end of September 2025 was 40.35 million, a slight decrease of 0.07% from the previous month, indicating a potential for further capacity reduction [23]. - The report highlights the narrowing of losses in pig farming, with self-breeding losses at -89.33 CNY per head and purchased piglet losses at -179.72 CNY per head, showing improvement compared to the previous week [27]. - The average price of broiler chicks increased to 3.58 CNY per chick, while the average price of white feather broilers rose to 7.09 CNY/kg, indicating a slight recovery in poultry prices [29][32]. - The report emphasizes the potential for investment opportunities in leading companies within the industry, particularly in pig farming, poultry farming, feed production, animal health, and pet food sectors [44]. Summary by Sections Market Review - The SW agriculture, forestry, animal husbandry, and fishery industry slightly underperformed the CSI 300 index, with a decline of 1.1% from October 17 to October 30, 2025 [11]. - Only a few sub-sectors recorded positive returns, with planting and agricultural product processing increasing by 1.47% and 0.44% respectively [14]. - Over half of the stocks in the industry recorded positive returns during the same period [15]. Industry Key Data - The average price of live pigs increased from 11.17 CNY/kg to 12.56 CNY/kg [23]. - The breeding sow inventory was 40.35 million, slightly down by 0.07% [23]. - The average prices for corn and soybean meal showed slight declines, with corn at 2242.16 CNY/ton and soybean meal at 3028 CNY/ton [25]. - Losses in pig farming narrowed, with self-breeding losses at -89.33 CNY per head [27]. Company Insights - The Q3 performance of pig and chicken farming companies showed a year-on-year decline in profitability due to lower prices compared to the previous year [35]. - Leading companies such as Muyuan Foods and Wens Foodstuffs are highlighted for their market positions and potential for recovery [44].

Core Viewpoint - Shenyuan Biological is a leading enterprise in the field of veterinary synthetic peptide vaccines in China, with a focus on research, production, and sales of veterinary biological products [1] Group 1: Business Performance - In Q3 2025, Shenyuan Biological reported revenue of 238 million yuan, ranking 10th in the industry, significantly lower than the top company, Zhongmu Co., which had 4.442 billion yuan, and the second, Ruipu Biological, with 2.544 billion yuan [2] - The net profit for the same period was -3.0229 million yuan, placing the company 12th in the industry, far behind Ruipu Biological's 391 million yuan and KQ Biological's 337 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Shenyuan Biological's debt-to-asset ratio was 8.94%, an increase from 6.72% year-on-year, but still below the industry average of 28.36% [3] - The gross profit margin for Q3 2025 was 59.49%, down from 61.12% year-on-year, yet higher than the industry average of 40.13% [3] Group 3: Executive Compensation - The chairman, Nie Dongsheng, received a salary of 1.1286 million yuan in 2024, a decrease of 49,000 yuan from 2023 [4] - The general manager, Zhang Zhen, had a salary of 990,000 yuan in 2024, an increase of 46,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 30.87% to 12,400, while the average number of circulating A-shares held per account decreased by 23.59% to 33,100 [5]

Core Viewpoint - 科前生物 is a leading company in the veterinary biological products sector in China, focusing on animal vaccine research and development, with strong financial performance and growth potential in the coming years [1][2][5]. Financial Performance - In Q3 2025, 科前生物 reported revenue of 738 million yuan, ranking 8th in the industry, with the top competitor 中牧股份 generating 4.442 billion yuan [2]. - The net profit for the same period was 337 million yuan, placing the company 2nd in the industry, with 瑞普生物 leading at 391 million yuan [2]. - The company's main business, veterinary biological products, accounted for 94.64% of total revenue, while other segments contributed 4.46% [2]. Profitability and Debt Management - As of Q3 2025, 科前生物's asset-liability ratio was 12.21%, lower than the previous year's 12.94% and significantly below the industry average of 28.36%, indicating strong debt repayment capability [3]. - The gross profit margin was 66.96%, an increase from 64.01% year-on-year and higher than the industry average of 40.13%, reflecting robust profitability [3]. Management and Shareholder Information - The chairman, 陈慕琳, received a salary of 1.6389 million yuan in 2024, up from 1.591 million yuan in 2023, an increase of 47,900 yuan [4]. - As of September 30, 2025, the number of A-share shareholders increased by 2.41% to 9,713, while the average number of shares held per shareholder decreased by 2.36% [5]. Growth Prospects - The company has been actively engaged in new product development, obtaining four new veterinary drug registration certificates in the first half of 2025, including a new inactivated vaccine for pigs [5][6]. - Forecasts suggest that 科前生物's revenue will grow to 1.038 billion yuan in 2025, 1.200 billion yuan in 2026, and 1.395 billion yuan in 2027, with net profits projected at 428 million yuan, 519 million yuan, and 610 million yuan respectively [5][6].